Floatz logo

FLUOROURACILUM

KRAS/NRAS Mutation

Cardiff OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the KRAS/NRAS Mutation cohort.

Asset / SponsorPhaseRating
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937
Cardiff Oncology
Phase 2CCC
Eloxatin
Cardiff Oncology
Phase 2CCC
Irinotecan
Cardiff Oncology
Phase 2CCC
Calcium folinate pentahydrate
Cardiff Oncology
Phase 2CCC
(+)-VINCRISTINE
Cardiff Oncology
Phase 2CCC

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →